Search alternatives:
small decrease » small increased (Expand Search)
dramatic » aromatic (Expand Search)
small decrease » small increased (Expand Search)
dramatic » aromatic (Expand Search)
-
661
-
662
-
663
-
664
Microarray analysis from GEO database showed TNFAIP9 was enhanced in CKD patients and mice.
Published 2025Subjects: -
665
Overexpression of TNFAIP9 alleviated the renal fibrosis caused by 5/6 Nx in C57 mice.
Published 2025Subjects: -
666
Overexpression of TNFAIP9 inhibits the weight loss caused by 5/6 Nx in C57 mice.
Published 2025Subjects: -
667
Overexpression of TNFAIP9 inhibited the TNF-α-induced inflammation in HK-2 cells.
Published 2025Subjects: -
668
-
669
Overexpression of TNFAIP9 remitted the renal inflammation caused by 5/6 Nx in C57 mice.
Published 2025Subjects: -
670
-
671
Overexpression of TNFAIP9 inhibited the TGF-β-induced fibrosis in HK-2 cells.
Published 2025Subjects: -
672
Overexpression of TNFAIP9 counteracted the renal damage caused by 5/6 Nx in C57 mice.
Published 2025Subjects: -
673
Table 3_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx
Published 2025“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”
-
674
Table 7_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx
Published 2025“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”
-
675
Image 1_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.jpg
Published 2025“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”
-
676
Table 8_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx
Published 2025“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”
-
677
Table 4_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx
Published 2025“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”
-
678
Table 6_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx
Published 2025“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”
-
679
Table 2_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx
Published 2025“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”
-
680
Table 1_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx
Published 2025“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”